Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion Zavesca AWP

Executive Summary

Actelion/Celltech's oral Gaucher disease therapy Zavesca (miglustat) is priced at an AWP of $9,337 for a 30-day supply of 90 capsules. Zavesca was approved as second-line therapy to Genzyme's Cerezyme (imiglucerase) in July (1"The Pink Sheet" Aug. 4, 2003, p. 37). CuraScript has been selected as Zavesca's exclusive pharmacy distributor...

You may also be interested in...



Actelion Zavesca Clears FDA; Available For Gaucher Patients By Year-End

Actelion/Celltech's Zavesca will be available to Gaucher disease patients before the end of the year following FDA approval of the drug July 31

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel